- Home
- BETR vs NPCE Comparison
BETR vs NPCE Comparison
Compare BETR & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BETR | NPCE |
|---|---|---|
| Founded | 2014 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 492.2M | 485.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BETR | NPCE |
|---|---|---|
| Price | $36.66 | $14.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $40.00 | $18.33 |
| AVG Volume (30 Days) | ★ 330.0K | 192.0K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $99,986,000.00 |
| Revenue This Year | $51.61 | $0.93 |
| Revenue Next Year | $62.67 | $25.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.13 |
| 52 Week Low | $9.50 | $7.56 |
| 52 Week High | $94.06 | $18.97 |
Technical Indicators
Market Signals| Indicator | BETR | NPCE |
|---|---|---|
| Relative Strength Index (RSI) | 56.87 | 42.84 |
| Support Level | $30.98 | $14.02 |
| Resistance Level | $42.09 | $16.96 |
| Average True Range (ATR) | 3.31 | 0.80 |
| MACD | 0.92 | 0.04 |
| Stochastic Oscillator | 74.81 | 47.47 |
Price Performance
Historical ComparisonAbout BETR Better Home & Finance Holding Company
Better Home & Finance Holding Co is a digital-first homeownership company whose services include mortgage, real estate, title, and homeowners insurance. The company has combined technology innovation and fresh thinking with a deep customer focus with the goal of revolutionizing the homeownership industry.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.